Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. (2022)
Attributed to:
Evaluating new healthcare technologies in cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0269192
PubMed Identifier: 35653395
Publication URI: http://europepmc.org/abstract/MED/35653395
Type: Journal Article/Review
Volume: 17
Parent Publication: PloS one
Issue: 6
ISSN: 1932-6203